Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Keith Stuart(Brigham and Women's Hospital), Susan Sheehan(Jackson Laboratory), Pankaj Bhargava(University of North Carolina at Chapel Hill), Kerry Horgan(Beth Israel Deaconess Medical Center), David P. Ryan(East Carolina University), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Alona Muzikansky(Johns Hopkins University), Peter C. Enzinger(Dana-Farber Cancer Institute), K Hale(Beth Israel Deaconess Medical Center)
Cited by 388
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k